CryoPort (NASDAQ:CYRX) CEO Jerrell Shelton Sells 2,894 Shares

CryoPort, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 2,894 shares of the stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $8.18, for a total transaction of $23,672.92. Following the completion of the sale, the chief executive officer owned 1,051,607 shares of the company’s stock, valued at approximately $8,602,145.26. This represents a 0.27% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 16th, Jerrell Shelton sold 7,918 shares of CryoPort stock. The stock was sold at an average price of $8.00, for a total value of $63,344.00.

CryoPort Trading Up 3.2%

CYRX stock opened at $8.41 on Thursday. The stock has a market cap of $419.32 million, a P/E ratio of 6.37 and a beta of 1.69. The stock’s fifty day simple moving average is $8.90 and its two-hundred day simple moving average is $9.32. CryoPort, Inc. has a 1-year low of $4.63 and a 1-year high of $11.45.

CryoPort (NASDAQ:CYRX) last released its earnings results on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $45.45 million for the quarter, compared to the consensus estimate of $42.92 million. CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%. As a group, analysts forecast that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Trading of CryoPort

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. increased its holdings in shares of CryoPort by 37.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock worth $14,208,000 after buying an additional 408,263 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of CryoPort by 663.2% during the 3rd quarter. SG Americas Securities LLC now owns 127,280 shares of the company’s stock worth $1,207,000 after acquiring an additional 110,602 shares during the last quarter. Bullseye Asset Management LLC grew its position in CryoPort by 23.0% in the second quarter. Bullseye Asset Management LLC now owns 260,168 shares of the company’s stock worth $1,941,000 after acquiring an additional 48,605 shares in the last quarter. Thematics Asset Management increased its stake in CryoPort by 12.8% in the second quarter. Thematics Asset Management now owns 1,914,885 shares of the company’s stock valued at $14,285,000 after acquiring an additional 216,937 shares during the last quarter. Finally, Mak Capital One LLC bought a new position in CryoPort in the third quarter valued at $7,756,000. 92.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

CYRX has been the subject of several research reports. Needham & Company LLC increased their price objective on CryoPort from $12.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen cut CryoPort from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, CryoPort currently has an average rating of “Moderate Buy” and an average target price of $12.94.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.